EMA-approved (2014)
Ayton S, Wang Y, Diouf I, Schneider JA, Brockman J, Morris MC et al (2020) Brain iron is associated with accelerated cognitive decline in people with Alzheimer pathology
For context, semaglutide (injectable) and tirzepatide (injectable) show much larger average losses in high-quality trials, but they are injectable prescription medicines with different mechanisms and risk profiles
The FDA approved Wegovy for cardiovascular risk reduction in adults with established cardiovascular disease who are also overweight in March 2024, which opened the door for Medicare coverage in that specific population
Key timing considerations: Broader Tmax window (8 to 72 hours) means less precision in predicting peak effects Dual GIP/GLP-1 mechanism may produce a different side effect timing pattern than pure GLP-1 agonists Body aches and muscle pain may peak later than GI symptoms, around 24 to 48 hours post-injection Consider how tirzepatide affects metabolism throughout the weekly cycle The appetite suppression timeline may differ from semaglutide due to the dual mechanism Dose escalation timing: Tirzepatide starts at 2.5mg weekly, escalating to 5mg after 4 weeks
But beware of them
